Barclays
ALBO

Barclays’s Albireo Pharma Inc ALBO Stock Holding History

Barclays’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-6,163
Closed -$133K – 5520
2022
Q4 		$133K Buy
6,163
+4,160
+208% +$87.9K ﹤0.01% 4063
2022
Q3 		$39K Buy
2,003
+1,138
+132% +$23.5K ﹤0.01% 3860
2022
Q2 		$17K Sell
865
-1,952
-69% -$51.5K ﹤0.01% 4473
2022
Q1 		$84K Sell
2,817
-17,663
-86% -$517K ﹤0.01% 3863
2021
Q4 		$477K Buy
20,480
+13,523
+194% +$360K ﹤0.01% 3228
2021
Q3 		$217K Buy
6,957
+4,599
+195% +$142K ﹤0.01% 3584
2021
Q2 		$83K Sell
2,358
-15,712
-87% -$511K ﹤0.01% 3921
2021
Q1 		$637K Buy
18,070
+8,693
+93% +$321K ﹤0.01% 3053
2020
Q4 		$352K Sell
9,377
-638
-6% -$23.2K ﹤0.01% 3459
2020
Q3 		$334K Buy
10,015
+2,699
+37% +$78.6K ﹤0.01% 3514
2020
Q2 		$195K Buy
7,316
+3,150
+76% +$74.3K ﹤0.01% 4086
2020
Q1 		$68K Sell
4,166
-6,719
-62% -$148K ﹤0.01% 5033
2019
Q4 		$277K Buy
10,885
+5,521
+103% +$110K ﹤0.01% 4782
2019
Q3 		$107K Sell
5,364
-1,294
-19% -$33.5K ﹤0.01% 5432
2019
Q2 		$215K Buy
6,658
+3,982
+149% +$133K ﹤0.01% 5044
2019
Q1 		$86K Buy
2,676
+2,523
+1,649% +$67.9K ﹤0.01% 5486
2018
Q4 		$4K Sell
153
-3,375
-96% -$89.2K ﹤0.01% 6562
2018
Q3 		$117K Buy
3,528
+2,861
+429% +$93.6K ﹤0.01% 5418
2018
Q2 		$23K Sell
667
-5,226
-89% -$169K ﹤0.01% 6115
2018
Q1 		$192K Sell
5,893
-807
-12% -$27.2K ﹤0.01% 4863
2017
Q4 		$172K Buy
+6,700
New +$170K ﹤0.01% 4808
2013
Q3 		– Sell
-3
Closed -$391 – 7663
2013
Q2 		$0 Buy
+3
New +$312 ﹤0.01% 7674

Other funds holding ALBO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Barclays's ALBO Position: Q1 2023 in Review

Barclays sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 6,163 shares — an estimated $133K sold.

Barclays first reported a position in ALBO in Q2 2013 and held it in 22 quarters. The position peaked at $637K in Q1 2021. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.

  • Barclays reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
  • Barclays sold 6,163 Albireo Pharma Inc shares in Q1 2023, an estimated $133K.
  • Barclays first reported a position in Albireo Pharma Inc in Q2 2013 and held it in 22 quarters.
  • Barclays's Albireo Pharma Inc position peaked at $637K in Q1 2021.
  • 3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.

Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.